Camp4 Therapeutics secures TGA clearance for CMP-002, enabling up to $50.1M second closing

Camp4 Therapeutics received Australian regulatory clearance to start its Phase 1/2 trial of CMP-002 and triggered a financing milestone enabling up to $50.1 million in additional proceeds.Key Highlights:Original SEC Filing: Camp4 Therapeutics Corp [ CAMP ] - 8-K - Jul. 27, 2026This is an AI-powered…

Camp4 Therapeutics received Australian regulatory clearance to start its Phase 1/2 trial of CMP-002 and triggered a financing milestone enabling up to $50.1 million in additional proceeds.

Key Highlights:

Received TGA and local HREC clearance to initiate Phase 1/2 trial of CMP-002 for SYNGAP1-related disorder, allowing trial sites in Australia.
Clearance satisfied the CTA Milestone under the Sept 9, 2025 Securities Purchase Agreement.
Company obtained a Price Threshold Waiver and satisfied the Second Closing Trigger under the Purchase Agreement.
Subject to remaining conditions and investor participation, Camp4 is eligible to receive up to ~$50.1M gross for up to 32,721,172 shares (or pre-funded warrants); closing expected ~Aug 3, 2026.
Australia chosen for initial filing due to SYNGAP1 expertise and trial infrastructure; company pursuing broader international filings.

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.